JP2014526440A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526440A5
JP2014526440A5 JP2014528563A JP2014528563A JP2014526440A5 JP 2014526440 A5 JP2014526440 A5 JP 2014526440A5 JP 2014528563 A JP2014528563 A JP 2014528563A JP 2014528563 A JP2014528563 A JP 2014528563A JP 2014526440 A5 JP2014526440 A5 JP 2014526440A5
Authority
JP
Japan
Prior art keywords
hdl
pharmaceutical composition
apo
seq
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014528563A
Other languages
English (en)
Japanese (ja)
Other versions
JP6078067B2 (ja
JP2014526440A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/052925 external-priority patent/WO2013033260A1/en
Publication of JP2014526440A publication Critical patent/JP2014526440A/ja
Publication of JP2014526440A5 publication Critical patent/JP2014526440A5/ja
Application granted granted Critical
Publication of JP6078067B2 publication Critical patent/JP6078067B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014528563A 2011-08-29 2012-08-29 炎症誘発性状態の治療および予防のためのｈｄｌ関連分子の使用 Expired - Fee Related JP6078067B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161528447P 2011-08-29 2011-08-29
US61/528,447 2011-08-29
US201261624333P 2012-04-15 2012-04-15
US61/624,333 2012-04-15
US201261646772P 2012-05-14 2012-05-14
US61/646,772 2012-05-14
PCT/US2012/052925 WO2013033260A1 (en) 2011-08-29 2012-08-29 Use of hdl-related molecules to treat and prevent proinflammatory conditions

Publications (3)

Publication Number Publication Date
JP2014526440A JP2014526440A (ja) 2014-10-06
JP2014526440A5 true JP2014526440A5 (enExample) 2016-02-12
JP6078067B2 JP6078067B2 (ja) 2017-02-08

Family

ID=47756845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528563A Expired - Fee Related JP6078067B2 (ja) 2011-08-29 2012-08-29 炎症誘発性状態の治療および予防のためのｈｄｌ関連分子の使用

Country Status (8)

Country Link
US (2) US9241976B2 (enExample)
EP (1) EP2751126B1 (enExample)
JP (1) JP6078067B2 (enExample)
KR (1) KR20140063747A (enExample)
CN (1) CN104039810A (enExample)
AU (1) AU2012301955A1 (enExample)
CA (1) CA2846865A1 (enExample)
WO (1) WO2013033260A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426817B2 (en) 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
WO2018190896A1 (en) * 2017-04-13 2018-10-18 Lipimetix Development, Inc. Apoe mimetic peptide compositions
CN120085016A (zh) * 2025-03-14 2025-06-03 北京大学第三医院（北京大学第三临床医学院） 一种apoa1作为生物标志物在制备用于监测结肠炎症活动度的产品中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DK145385D0 (da) 1985-03-29 1985-04-01 Novo Industri As Monoklonalt antistof til immunkemisk analyse
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5114863A (en) 1986-09-30 1992-05-19 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Immunosorbant assay for α-1-antitrypsin, kit employing said assay, monoclonal antibody to α-1-antitrypsin, and hybridoma for producing said monoclonal antibody
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
SE8904007D0 (sv) 1989-11-28 1989-11-28 Ferring Ab Monoklona antikroppar och diagnostiseringsmetod
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
RU2152787C2 (ru) * 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
US20030027216A1 (en) 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
US5891641A (en) 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
US5955582A (en) 1997-09-26 1999-09-21 Beckman Coulter, Inc. Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20050214760A1 (en) 2002-01-07 2005-09-29 Johns Hopkins University Biomarkers for detecting ovarian cancer
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
AU2003247610A1 (en) 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US7927791B2 (en) 2002-07-24 2011-04-19 Ptc Therapeutics, Inc. Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mRNA decay
NZ562192A (en) 2002-08-06 2009-07-31 Ciphergen Biosystems Inc Use of biomarkers for detecting ovarian cancer
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
JP2007504840A (ja) 2003-05-12 2007-03-08 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Ｇｒｐ９４ベース組成物及びそれらの使用方法
EP1658497B1 (en) 2003-08-25 2008-12-03 Marc Ramael A method and kit for the quantitative and/or qualitative detection of components in a sample
US20070031379A1 (en) 2004-01-09 2007-02-08 Lee Kyu H Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same
US20060147946A1 (en) 2004-01-27 2006-07-06 Pinchas Akiva Novel calcium channel variants and methods of use thereof
WO2005093413A2 (en) 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
US9488655B2 (en) 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
US7670792B2 (en) 2004-07-14 2010-03-02 The Regents Of The University Of California Biomarkers for early detection of ovarian cancer
US9487575B2 (en) * 2004-07-14 2016-11-08 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
EP1789805B1 (en) 2004-07-14 2010-09-15 The Regents of The University of California Biomarker for early detection of ovarian cancer
EP1796708A4 (en) * 2004-09-02 2009-07-08 Cognosci Inc IMPROVED APO-E ANALOGS AND USE METHOD THEREFOR
JP2008513031A (ja) 2004-09-20 2008-05-01 プロテオジェニックス， インコーポレイテッド 胎児異数性の診断
NZ555826A (en) * 2004-12-06 2009-11-27 Univ California Methods for improving the structure and function of arterioles
US7427662B2 (en) 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
KR101310000B1 (ko) 2005-03-11 2013-09-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘
US20080293639A1 (en) 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP2269623A1 (en) * 2005-04-29 2011-01-05 The Regents of The University of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7604948B2 (en) 2005-05-05 2009-10-20 The Regents Of The University Of California Biomarkers for diagnosing an autism spectrum disorder
US20100173788A1 (en) 2005-06-21 2010-07-08 Vermillion, Inc. Biomarkers for breast cancer
US7575876B2 (en) 2005-10-27 2009-08-18 The University Of Washington Biomarkers for neurodegenerative disorders
EP2537525A1 (en) 2005-12-16 2012-12-26 Electrophoretics Limited Diagnosis and prognosis of colorectal cancer
KR100725642B1 (ko) * 2006-01-20 2007-06-07 충남대학교산학협력단 저밀도 지단백질에 대해 항산화성을 갖는 펩타이드
US7723045B2 (en) 2006-02-10 2010-05-25 The Regents Of The University Of California Assays to predict atherosclerosis and dysfunctional high-density lipoprotein
CA2690376A1 (en) * 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Apoa-1 peptide mimetics
CA2704729C (en) * 2007-08-28 2020-06-23 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
JP2010537638A (ja) * 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
JP2009092440A (ja) 2007-10-04 2009-04-30 Shimadzu Corp 卵巣癌の診断システム及び卵巣癌の診断方法

Similar Documents

Publication Publication Date Title
JP2012525844A5 (enExample)
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
JP2010518079A5 (enExample)
RU2012139432A (ru) Полипептиды
CN105008395B (zh) 长效单链胰岛素类似物
JP2010031018A5 (enExample)
WO2012142320A8 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
JP2013504589A5 (enExample)
JP2013127002A5 (enExample)
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
JP2011528332A (ja) 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置
EA201200515A1 (ru) Полипептиды и их применение
CN103476933A (zh) 白介素1受体的拮抗剂
JP2008513367A5 (enExample)
JP2013510169A5 (enExample)
RU2015110114A (ru) Ангиотензин в лечении состояний головного мозга
US20140322332A1 (en) Antagonists of muc1
Hua et al. Substance P promotes epidural fibrosis via induction of type 2 macrophages
WO2022251102A2 (en) Tgf-beta therapeutics for age disease
JP2018515459A (ja) 自己免疫障害及び炎症障害を治療及び／又は予防するための短い合成ペプチド
JP2014526440A5 (enExample)
WO2013104928A1 (en) Peptide and uses thereof
ES2979305T3 (es) Composiciones y métodos para tratar enfermedades metabólicas
CN107987147B (zh) 一种mg53多聚体制备方法及其用途
CN117946213A (zh) 治疗癌症的肽